Friday - May 16, 2025

LOGIN  |  REGISTER
Astria Therapeutics
Terns Pharmaceuticals

Mettler-Toledo to Host Fourth Quarter 2024 Earnings Conference Call

January 10, 2025 | Last Trade: US$1,157.40 14.04 1.23

COLUMBUS, Ohio / Jan 10, 2025 / Business Wire / Mettler-Toledo International Inc. (NYSE: MTD) announced it will release its fourth quarter 2024 financial results after the market close on Thursday, February 6, 2025. The Company will host a conference call the following morning at 8:30 a.m. Eastern Time to discuss the results. To listen to the live audio webcast of the call, visit Events and Presentations on the Investor section of the Company’s website, investor.mt.com.

METTLER TOLEDO (NYSE: MTD) is a leading global supplier of precision instruments and services. We have strong leadership positions in all of our businesses and believe we hold global number-one market positions in most of them. We are recognized as an innovation leader and our solutions are critical in key R&D, quality control, and manufacturing processes for customers in a wide range of industries including life sciences, food, and chemicals. Our sales and service network is one of the most extensive in the industry. Our products are sold in more than 140 countries and we have a direct presence in approximately 40 countries. With proven growth strategies and a focus on execution, we have achieved a long-term track record of strong financial performance. For more information, please visit www.mt.com.

Stock Quote

Last Trade: US$1,157.40
Daily Change: 14.04 1.23
Daily Volume: 69,822
Market Cap: US$24.420B

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page